Flexing its newfound wealth, BioNTech snaps up a TCR platform and manufacturing site as Gilead exits
BioNTech is putting some of its new-found wealth from its star mRNA vaccine for Covid-19 to use. The biotech $BNTX, which now weighs in with a behemoth $56 billion market cap, is buying a cell therapy R&D platform plus a manufacturing site from Gilead’s Kite sub.
The deal — which rather oddly comes without any numbers from the public German biotech company — gives BioNTech Kite’s R&D IP for its personalized neoantigen TCR work as well as the manufacturing center it has in Gaithersburg, MD, which supplies clinical trial product.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,300+ biopharma pros reading Endpoints daily — and it's free.